Sanofi CEO Paul Hud­son con­tin­ues hunt for new tech, spear­ing a deal with organoid start­up

Sanofi is dip­ping its toes in­to a wide range of new tech­nolo­gies as CEO Paul Hud­son looks to find its next big break­through. His lat­est pick comes from an emerg­ing field that’s had plen­ty of buzz but few tan­gi­ble re­sults in drug de­vel­op­ment so far.

The French phar­ma an­nounced on Tues­day a deal with Prel­lis Bi­o­log­ics, a new biotech that claims to have de­vel­oped an organoid sys­tem in its labs that can mim­ic the hu­man im­mune sys­tem. Al­though the start­up has on­ly raised a mod­est sum by mod­ern biotech stan­dards — it an­nounced a $14.5 mil­lion Se­ries B in De­cem­ber — its tech­nol­o­gy has at­tract­ed the in­ter­est of large com­pa­nies. In Jan­u­ary, the com­pa­ny al­so an­nounced a li­cens­ing deal with Bris­tol My­ers Squibb.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN